No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ELDN Eledon Pharmaceuticals
- 1.860
- -0.130-6.53%
Close Apr 19 16:00 ET
- 1.950
- +0.090+4.85%
Post 19:41 ET
46.15MMarket Cap-1134P/E (TTM)
2.183High1.770Low420.86KVolume2.110Open1.990Pre Close817.50KTurnover2.34%Turnover RatioLossP/E (Static)24.81MShares2.95052wk High0.55P/B33.51MFloat Cap1.07052wk Low--Dividend TTM18.02MShs Float4864.865Historical High--Div YieldTTM20.75%Amplitude1.070Historical Low1.942Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Watching Eledon Pharmaceuticals, Acumen Pharmaceuticals; Shares See Volume On TipRanks Article Titled "These 2 'Strong Buy' Penny Stocks Are Poised for Over 300% Gains, Say Analysts"
Eledon Pharmaceuticals Risks Shareholder Equity Dilution Amidst Private Placement and Potential Stock Issuances
Eledon Pharmaceuticals: A Strong Buy on the Back of Promising Clinical Trials and a Solid Financial Footing
Express News | Eledon Pharma Q4 2023 GAAP EPS $(0.32) Beats $(0.39) Estimate
Eledon PhaDrmaceuticals 4Q Loss/Shr 32c >ELDN
Eledon PhaDrmaceuticals 4Q Loss/Shr 32c >ELDN
Press Release: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney r
Comments
$Eledon Pharmaceuticals(ELDN.US$ 10%🟢
First-ever Transplant of Genetically Modified Kidney
⇒ Pig to a Human
⇒ Use of Tegoprubart (anti-CD40L antibody)
⇒ Immunosuppressive treatment
$Bristol-Myers Squibb(BMY.US$
⇒ First CAR T Cell Therapy approval in the EU
⇒ Abecma
First-ever Transplant of Genetically Modified Kidney ⇒ Pig to a Human
⇒ Use of Tegoprubart (anti-CD40L antibody)
⇒ Immunosuppressive treatment
$Bristol-Myers Squibb(BMY.US$
⇒ First CAR T Cell Therapy approval in the EU
⇒ Abecma
3
1
Still interested!
$Eledon Pharmaceuticals(ELDN.US$ preliminary data from the study, which involved 11 participants, highlighted tegoprubart’s efficacy in preventing kidney transplant rejection, along with its general safety and tolerability. I need to keep this in mind. its there kidney drug
Deeply Disappointing /disheartening!
$Eledon Pharmaceuticals(ELDN.US$ It a terrible shame that the guy died! it sure looked like the rejection meds were working for the first few weeks/month. Then started to show signs of rejection of the Pig heart. Now he’s gone! Yes i think thats why this is dropping? but im just saddened because if it woulda worked? It would have been a real game changer for people with sever heart disease and saved countless lives! Well as long as its not postponed? tomorrow...
1
1
$Eledon Pharmaceuticals(ELDN.US$ Bid and Ask > 2 Cents not Eagles and Gooses Food then must Delete 👊👹💩
$Eledon Pharmaceuticals(ELDN.US$ Blardy manipulated ticker...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
stockhub : Yes, it is a buy
Small quantity though